

06-13-07

CYC

Express Mail No. EB 132 601 914 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Sommadossi *et al.*

Confirmation No.: 9998

Patent No. 6,914,054

Issued: July 5, 2005

Serial No.: 09/864,078

Art Unit: 1623

Filed: May 23, 2001

Examiner: Howard V. Owens Jr.

For: METHODS AND COMPOSITIONS FOR  
TREATING HEPATITIS C VIRUS

Attorney Docket No: 11874-014-999  
CAM: 417451-999014  
IDX 1007

**REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322**

Attn: Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

**Certificate**  
**JUN 18 2007**  
**of Correction**

Pursuant to 35 U.S.C. § 254 and 37 C.F.R. § 1.322, Patentee hereby respectfully requests the issuance of a Certificate of Correction in connection with the above-identified patent. The corrections are described below and on the attached Form PTO/SB/44, which is submitted in duplicate herewith.

In claim 4, line 15, the text "pharmaceutically acceptable thereof," should be replaced with -- pharmaceutically acceptable salt thereof, --.

In claim 25, line 38, the text " $\beta$ -D-2'-C-branded" should be replaced with --  $\beta$ -D-2'-C-branched --.

In claim 26, line 42, the text " $\beta$ -D-2'-C-branded" should be replaced with --  $\beta$ -D-2'-C-branched --.

In claim 26, line 43, the text "nucleoside" should be replaced with -- ribonucleoside --.


These corrections reflect an amendment to the claims made in the amendment after Notice of Allowance dated May 3, 2004 for the instant application. Thus, the error occurred on the part of the U.S. Patent and Trademark Office.

**JUN 18 2007**

Please issue a Certificate of Correction in due course. As this error was on the part of the U.S. Patent and Trademark Office, no fee is believed to be due. However, the Commissioner is authorized to charge any required fee or credit any overpayments to Jones Day Deposit Account No. 50-3013 (order no. 417451-999016). A duplicate of this sheet is enclosed for accounting purposes.

Date: June 11, 2007

Respectfully submitted,



Dale Rieger

Reg. No. 43,045

**JONES DAY**  
222 East 41st Street  
New York, New York 10017  
(858) 314-1200

**JUN 18 2007**

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO. : 6,914,054  
 DATED : July 5, 2005  
 INVENTOR(S) : Jean-Pierre Sommadossi *et al.*

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 161, claim 4, line 15, the text "pharmaceutically acceptable thereof," should be replaced with -- pharmaceutically acceptable salt thereof, --.

Column 164, claim 25, line 38, the text " $\beta$ -D-2'-C-branded" should be replaced with -  $\beta$ -D-2'-C-branded --.

Column 164, claim 26, line 42, the text " $\beta$ -D-2'-C-branded" should be replaced with -  $\beta$ -D-2'-C-branded --.

Column 164, claim 26, line 43, the text "nucleoside" should be replaced with -- ribonucleoside --.

MAILING ADDRESS OF SENDER:  
 JONES DAY  
 222 East 41st Street  
 New York, New York 10017  
 (212) 326-3939  
 LAI-2876060v1  
 FORM PTO 1050

PATENT NO. 6,914,054

JUL 18 2007

=>

IDX 1007